Anti-Aβ3–10 monoclonal antibody 7B8 improves cognitive function and protects the blood-brain barrier in APP/PS1 mice by regulating the HMGB-1/RAGE/NF-κB pathway - Top-Institutions - MDSpire

Anti-Aβ3–10 monoclonal antibody 7B8 improves cognitive function and protects the blood-brain barrier in APP/PS1 mice by regulating the HMGB-1/RAGE/NF-κB pathway

  • By

  • Jiayu You

  • Qianshuo Liu

  • Xingqiang Li

  • April 30, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Neurology
    • Neuroscience
    • Alzheimer's Disease Research

  • #2

    Alzheimer's Disease Research Center, University of California San Francisco
    Alzheimer's Disease Research Center, University of California San Francisco

    San Francisco, CA

    Key Differentiators

    • Neurology
    • Neuroscience
    • Neuroimmunology

  • #3

    Mayo Clinic Alzheimer's Disease Research Center
    Mayo Clinic Alzheimer's Disease Research Center

    Rochester, MN

    Key Differentiators

    • Neurology
    • Neurodegenerative Diseases
    • Clinical Trials

  • #4

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Neurology
    • Neuroscience
    • Immunology

  • #5

    Washington University in St. Louis, Knight Alzheimer Disease Research Center
    Washington University in St. Louis, Knight Alzheimer Disease Research Center

    St. Louis, MO

    Key Differentiators

    • Neurology
    • Neuroscience
    • Alzheimer's Disease

Original Source(s)

Anti-Aβ3–10 monoclonal antibody 7B8 improves cognitive function and protects the blood-brain barrier in APP/PS1 mice by regulating the HMGB-1/RAGE/NF-κB pathway

  • by Jiayu You, Qianshuo Liu, Xingqiang Li

  • April 30, 2026

Related Content

Volume of parasagittal dura is associated with blood markers of systemic inflammation

This Week’s CGT News: CAR-T Breaks New Ground in Alzheimer’s

First CAR-T approach for Alzheimer’s reduces amyloid plaques in mice, while cell and gene therapies advance across blood cancers, retinal disease, amyloidosis, and FSHD

  • May 11, 2026

  • 7 min
The immune-endothelial axis in neurovascular pathophysiology: a framework for targeted interventions